Format

Send to

Choose Destination
Expert Opin Emerg Drugs. 2015;20(4):531-6. doi: 10.1517/14728214.2015.1113254. Epub 2015 Nov 19.

What is the future of PEGylated therapies?

Author information

1
a The Russell H. Morgan Department of Radiology and Radiological Sciences , Johns Hopkins University School of Medicine , Baltimore , MD 21231 , USA.
2
b The Center for Nanomedicine at the Wilmer Eye Institute , Johns Hopkins University School of Medicine , Baltimore , MD 21231 , USA Tel: 443-287-7365 ; Fax: 410-614-3147.
3
c College of Pharmacy , SungKyunKwan University , Suwon 440-746 , Korea Tel: 82-31-290-7704 ; Fax: 82-31-290-7724 ; E-mail: kclee@skku.edu.

Abstract

The tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new biologic therapies. PEGylation is the first successful technology to improve pharmacokinetic (PK) profiles of therapeutic agents and has been applied in the clinic for over 25 years. Over 10 PEGylated therapeutics have entered the clinic since the early 1990 s, and new PEGylated agents continue to expand clinical pipelines and drug patent life. PEGylation is the most established half-life extension technology in the clinic with proven safety in humans for over two decades. Still, it is one of the most evolving and emerging technologies that will be applied for the next two decades.

KEYWORDS:

PEGylation; half-life extension; peptide delivery; protein delivery

PMID:
26583759
PMCID:
PMC4908577
DOI:
10.1517/14728214.2015.1113254
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center